Decoded

What does it take to turn a two-person startup in Paris into a $6.8 billion exit, and then do it all over again for 200 other founders?

In this episode of Decoded, Dr. Jurgi Camblong speaks with Bernard Liautaud, co-founder of BusinessObjects and Managing Partner at Balderton Capital, one of Europe's leading venture capital firms backing category-defining companies like Revolut, Wayve, and Quantum Systems.

Bernard didn't just build a company. He built a category. Starting with two people in Paris in 1990, he helped define what business intelligence could be, took the company to NASDAQ, and sold it...

What happens when a world-class biologist decides that academic research isn't moving fast enough for patients? 

Dr. Keith Flaherty is a physician, scientist, and founder who obsesses over the "wiring of cells". As the Director of Clinical Research at the Mass General Hospital Cancer Center and a Professor of Medicine at Harvard Medical School, he has authored over 300 peer-reviewed research publications. But he didn't stop at academia. He went on to co-found Loxo Oncology and Scorpion Therapeutics, driving billions in acquisitions and fundamentally changing precision cancer care. 

In this episode, Keith joins Dr. Jurgi Camblong to...

What happens when the mind behind the Mars Rovers turns its attention to fighting cancer and developing next-generation medicines?
Today, Thomas Fuchs is the Chief AI Officer at Eli Lilly & Company, but he started his career at NASA, building the AI that helped rovers navigate the surface of Mars. He soon realized that the same math used to distinguish sand from rocks could be used to identify cancer cells on a pathology slide. He transitioned to healthcare, coined the term "computational pathology", and secured the first-ever FDA approval for an AI solution in cancer pathology after founding Paige...

Most doctors look at a tumor and see a disease. Professor Olivier Michielin sees a code waiting to be cracked. 

Starting his career in physics and training under Nobel Prize winner Martin Karplus, Olivier realized early on that he "would not be happy just talking to electrons". He pivoted to medicine to bring a data-driven, engineering mindset to oncology. Today, he is rewriting the rules of how we treat melanoma and other complex cancers by combining immunotherapy with advanced algorithms. 

In this episode, the "Tumor Hacker" joins Dr. Jurgi Camblong to discuss how he is us...

Are we practicing healthcare, or just "sick care"?

In this episode of Decoded, Jurgi Camblong sits down with Dr. Michael Snyder, Chair of Genetics at Stanford Medicine and one of the most cited scientists in the world, to challenge the status quo of modern medicine.

We monitor our cars with dashboards to prevent breakdowns, yet we wait until our bodies fail before seeking help. Dr. Snyder explains why the future of medicine isn't about treating illness—it's about predicting it.

In this episode, we cover:

The "Sick Care" Crisis: Why our cu...

Longevity is not luck. It is biology, variation, and human resilience expressed across generations - and we are only beginning to understand it. And few people have studied longevity more deeply than Professor Mayana Zatz, whose work with centenarians and supercentenarians is reshaping what we know about aging.

In this episode of Decoded, Dr. Jurgi Camblong speaks with one of the world’s leading geneticists and a pioneer in rare diseases, aging, and human longevity.

Based at the University of São Paulo, Mayana has followed more than 100,000 families to understand why some people develop sev...

In this episode, Dr. Jurgi Camblong travels to the University of Oxford to meet Professor Nicholas Proudfoot, one of the true pioneers of molecular biology. 

For more than five decades, Nick has helped decode life itself, revealing how genes are turned on and off, how RNA carries meaning beyond proteins, and how curiosity can drive discoveries that last a lifetime. 

Together, they revisit the early days of modern biology - a time before PCR or cloning - and trace how one generation of scientists transformed trial and error into the precision science we know today. 

A Conversation with Parminder Bhatia, Chief AI Officer, GE HealthCare

After three episodes with leaders in oncology and medicine - Prof. Malapelle (International Society of Liquid Biopsy), Dr. David Rhew (Microsoft), and Dr. Pedram Razavi (MSK), Jurgi turns to the question everyone’s asking:

How do we move from impressive demos to real impact at the bedside—at scale?

In this episode, Dr. Jurgi Camblong, Founder SOPHiA GENETICS, speaks with Parminder “Parry” Bhatia, Chief AI Officer at GE HealthCare, to unpack the hard parts of AI in medicine: earning clinical trust, fitting...

Cancer has been described for a long time, yet only now are we beginning to truly decode it.

In this episode of Decoded, Dr. Jurgi Camblong, Founder of SOPHiA GENETICS, speaks with Dr. Pedram Razavi, Director of Liquid Biopsy and Cancer Genomics at Memorial Sloan Kettering Cancer Center. 

From the first historical mentions of tumors to today’s breakthroughs in precision oncology, Dr. Razavi shares how genomics, liquid biopsy, and AI are reshaping the way we detect, treat, and even think about cancer. Along the way, Dr. Razavi shares personal stories - the human moments tha...

In this episode of Decoded, Dr. Jurgi Camblong, Founder SOPHiA GENETICS, speaks with Dr. David Rhew, Global Chief Medical Officer at Microsoft and adjunct professor at Stanford University, to explore how responsible AI, multimodal data, and collective intelligence are reshaping global healthcare.

From his early fascination with arcade games to his leadership at Microsoft, Dr. Rhew shares a unique journey that blends computer science, clinical practice, and visionary health technology.

Together, they explore:

How do we move from discovery to action in the fight against cancer?

In this inaugural episode of the Decoded podcast, Dr. Jurgi Camblong speaks with Professor Umberto Malapelle, one of the leading voices in molecular diagnostics and liquid biopsy, to explore how precision data is reshaping the fight against cancer.

Together, they decode the evolving role of pathology, tracing the shift from glass slides to genomic signals and the rise of liquid biopsy as a dynamic, non-invasive tool in cancer care.

Professor Malapelle reveals how integrating molecular insights is making diagnostics more...